Atossa Therapeutics Optimizes EVANGELINE Study for Efficient Breast Cancer Treatment Development

Atossa Therapeutics Optimizes EVANGELINE Study to Enhance Efficiency in Breast Cancer Treatment

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to innovative breast cancer therapies, announces a significant amendment to its Phase 2 EVANGELINE study for (Z)-endoxifen, targeting premenopausal women with early-stage ER+/HER2- breast cancer. This redesign, revealed on October 6, 2025, aims to streamline operational costs and accelerate the timeline for obtaining objective data, thus extending the company’s operational runway and ensuring judicious use of capital. The updated study structure reflects Atossa's strategic pivot towards greater efficiency and focus, vital for navigating the competitive landscape of oncology drug development.

The amended EVANGELINE study features a single-arm, open-label design, reducing the number of participants from 214 to between 40 to 65. This focused approach includes two distinct cohorts: Cohort A concentrates on patients with an initial Ki-67 of over 10%, implementing a two-stage futility rule that assesses the Week-4 Ki-67 ≤10% rate to facilitate timely decision-making. Conversely, Cohort B examines patients with an initial Ki-67 of less than 10%, evaluating their Week-24 objective response. These changes are strategically crafted to emphasize short-term endpoints that can better guide development decisions while maintaining stringent safety protocols throughout the study.

CEO Steven Quay underscores that the redesign enhances operational efficiency, financial discipline, and overall focus on patient safety. Despite the modifications, Atossa remains committed to rigorous data collection and safety oversight, ensuring that patient welfare is never compromised. The company’s recent data from the EVANGELINE run-in phase, presented at the 2024 San Antonio Breast Cancer Symposium, indicates a promising Week-4 Ki-67 ≤10% rate of 86%, supporting the rationale for the revised study design. As Atossa gears up for NDA-enabling activities for (Z)-endoxifen in 2026, this strategic amendment exemplifies the company’s dedication to advancing its clinical programs with both efficacy and safety at the forefront.

In addition to the study amendments, Atossa’s initiatives reflect a broader trend in the biopharmaceutical industry where companies are increasingly optimizing clinical trial designs to enhance operational efficiency. By reducing the cohort size and focusing on key endpoints, Atossa not only aims to expedite its drug development process but also to allocate resources more effectively in a highly competitive market.

As the company prepares for upcoming regulatory activities, the adjustments to the EVANGELINE study signify Atossa's proactive approach to navigating the complexities of breast cancer treatment development. By prioritizing efficient and effective clinical strategies, Atossa Therapeutics positions itself as a forward-thinking leader in the biopharmaceutical sector.